TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial With Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects With High Risk Myeloid and Lymphoid Neoplasms
Sponsor: Medigene AG
Terminated
The clinical trial is terminated after the completion of phase I without moving to Phase II.
Other terminated trials from Medigene AG
More terminations from Medigene AG
Other Feasibility trials with similar outcome
A PHASE1/PHASE2 clinical study on Feasibility and Safety, this trial is terminated or withdrawn. The trial is conducted by Medigene AG and has accumulated 11 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2019 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medigene AG
For direct contact, visit the study record on ClinicalTrials.gov .